JP2019505486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505486A5 JP2019505486A5 JP2018530079A JP2018530079A JP2019505486A5 JP 2019505486 A5 JP2019505486 A5 JP 2019505486A5 JP 2018530079 A JP2018530079 A JP 2018530079A JP 2018530079 A JP2018530079 A JP 2018530079A JP 2019505486 A5 JP2019505486 A5 JP 2019505486A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- osteoarthritis
- subject
- composition according
- cartilage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562264682P | 2015-12-08 | 2015-12-08 | |
| US62/264,682 | 2015-12-08 | ||
| PCT/US2016/065520 WO2017100400A2 (en) | 2015-12-08 | 2016-12-08 | Use of c-type natriuretic peptide variants to treat osteoarthritis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505486A JP2019505486A (ja) | 2019-02-28 |
| JP2019505486A5 true JP2019505486A5 (enExample) | 2020-01-23 |
| JP7104625B2 JP7104625B2 (ja) | 2022-07-21 |
Family
ID=59013378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530079A Active JP7104625B2 (ja) | 2015-12-08 | 2016-12-08 | 骨関節炎を処置するためのｃ型ナトリウム利尿ペプチド変異体の使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11202819B2 (enExample) |
| EP (2) | EP3386531B1 (enExample) |
| JP (1) | JP7104625B2 (enExample) |
| KR (1) | KR20180088459A (enExample) |
| CN (1) | CN108697766A (enExample) |
| AU (2) | AU2016365751B2 (enExample) |
| CA (1) | CA3007315A1 (enExample) |
| DK (1) | DK3386531T3 (enExample) |
| ES (1) | ES2901769T3 (enExample) |
| HR (1) | HRP20211908T1 (enExample) |
| HU (1) | HUE057083T2 (enExample) |
| IL (1) | IL259690B2 (enExample) |
| MX (1) | MX2018006986A (enExample) |
| PL (1) | PL3386531T3 (enExample) |
| PT (1) | PT3386531T (enExample) |
| RU (1) | RU2759679C2 (enExample) |
| WO (1) | WO2017100400A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017118693A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
| CA3008017C (en) | 2016-01-08 | 2024-01-02 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| BR112018011008A2 (en) | 2016-01-08 | 2018-12-04 | Ascendis Pharma Growth Disorders A/S | low npr-c binding controlled release cnp agonists |
| EP3400022A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low initial npr-b activity |
| LT3400019T (lt) | 2016-01-08 | 2022-12-12 | Ascendis Pharma Growth Disorders A/S | Cnp provaistai su prie žiedo fragmento prijungtu nešikliu |
| MX2018008050A (es) | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada. |
| HUE062117T2 (hu) | 2016-09-29 | 2023-09-28 | Ascendis Pharma Growth Disorders As | Kombinációs terápia szabályozott felszabadulású CNP agonistákkal |
| BR112020021966A2 (pt) * | 2018-04-27 | 2021-01-26 | Remy Biosciences, Inc. | dispositivos médicos, veículos de liberação e fabricação dos mesmos |
| WO2020165081A1 (en) * | 2019-02-11 | 2020-08-20 | Ascendis Pharma Growth Disorders A/S | Dry pharmaceutical formulations of cnp conjugates |
| WO2022115563A1 (en) * | 2020-11-25 | 2022-06-02 | Prolynx Llc | Extended release hydrogel conjugates of c-natriuretic peptides |
| EP4337957A1 (en) * | 2021-05-11 | 2024-03-20 | Texas Tech University System | Targeted selenium conjugates as countermeasures for pathogenic viruses and cells |
| MX2024007052A (es) * | 2021-12-07 | 2024-09-05 | Biomarin Pharm Inc | Terapia de dnc. |
| AR130935A1 (es) | 2022-11-02 | 2025-02-05 | Novo Nordisk As | Compuestos de cnp |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| WO2024194300A1 (en) | 2023-03-20 | 2024-09-26 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
| KR20250098109A (ko) * | 2023-12-21 | 2025-07-01 | 주식회사 펩트론 | 나트륨이뇨 펩타이드 유사체 및 이의 용도 |
| CN117801123B (zh) * | 2024-02-29 | 2024-05-03 | 天津凯莱英生物科技有限公司 | 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| JP2809533B2 (ja) | 1991-01-31 | 1998-10-08 | 壽之 松尾 | Ｃｎｐ類似体ペプチド |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| EP3620530A1 (en) | 2004-03-31 | 2020-03-11 | Kazuwa Nakao | Composition for increasing body height |
| ES2465141T3 (es) | 2004-03-31 | 2014-06-05 | Kazuwa Nakao | Remedio o medicamento preventivo para la artritis |
| AR069409A1 (es) * | 2007-11-21 | 2010-01-20 | Biomarin Pharm Inc | Variantes de peptidos natriureticos de tipo c |
| HRP20161739T1 (hr) | 2009-05-20 | 2017-03-10 | Biomarin Pharmaceutical Inc. | VARIJANTE NATRIURETIČNOG PEPTIDA C-tipa |
| CA2823066A1 (en) * | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
-
2016
- 2016-12-08 MX MX2018006986A patent/MX2018006986A/es unknown
- 2016-12-08 DK DK16852866.9T patent/DK3386531T3/da active
- 2016-12-08 RU RU2018124600A patent/RU2759679C2/ru active
- 2016-12-08 CA CA3007315A patent/CA3007315A1/en active Pending
- 2016-12-08 WO PCT/US2016/065520 patent/WO2017100400A2/en not_active Ceased
- 2016-12-08 AU AU2016365751A patent/AU2016365751B2/en active Active
- 2016-12-08 KR KR1020187019166A patent/KR20180088459A/ko active Pending
- 2016-12-08 EP EP16852866.9A patent/EP3386531B1/en active Active
- 2016-12-08 JP JP2018530079A patent/JP7104625B2/ja active Active
- 2016-12-08 HU HUE16852866A patent/HUE057083T2/hu unknown
- 2016-12-08 HR HRP20211908TT patent/HRP20211908T1/hr unknown
- 2016-12-08 PL PL16852866T patent/PL3386531T3/pl unknown
- 2016-12-08 ES ES16852866T patent/ES2901769T3/es active Active
- 2016-12-08 US US15/779,049 patent/US11202819B2/en active Active
- 2016-12-08 CN CN201680081329.2A patent/CN108697766A/zh active Pending
- 2016-12-08 EP EP21202207.3A patent/EP4019038A3/en active Pending
- 2016-12-08 PT PT168528669T patent/PT3386531T/pt unknown
-
2018
- 2018-05-29 IL IL259690A patent/IL259690B2/en unknown
-
2021
- 2021-12-03 US US17/541,992 patent/US12214015B2/en active Active
-
2024
- 2024-03-21 AU AU2024201852A patent/AU2024201852A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505486A5 (enExample) | ||
| RU2018124600A (ru) | Применение вариантов натрийуретического пептида типа с для лечения остеоартрита | |
| JP2016512552A (ja) | リツキシマブ導入療法とその後の酢酸グラチラマー療法 | |
| Voulgari et al. | Infliximab therapy in established rheumatoid arthritis: an observational study | |
| JP6208763B2 (ja) | 変形性関節症を治療するためのｐｅｄｆ−由来のポリペプチドの使用 | |
| RS57853B1 (sr) | Dozni režim fgf-18 jedinjenja | |
| Nakamagoe et al. | Polymyalgia rheumatica in a melanoma patient due to nivolumab treatment | |
| RS65680B1 (sr) | Peptid tpx-100 za ublažavanje bola zglobova kolena | |
| CN107661501A (zh) | 一种治疗强直性脊柱炎的药物组合物、药物靶点及其应用 | |
| Lejko-Zupanc et al. | A case of recurrent Candida parapsilosis prosthetic valve endocarditis: cure by medical treatment alone | |
| Sofat et al. | Recent clinical evidence for the treatment of osteoarthritis: what we have learned | |
| CN113423466B (zh) | 软骨病症的治疗剂 | |
| CN119546340A (zh) | 使用白细胞介素-17（il-17）拮抗剂选择性治疗肌腱病的方法 | |
| TWI491407B (zh) | 色素上皮衍生因子衍生之多胜肽於治療骨性關節炎之用途 | |
| JP2021523894A5 (enExample) | ||
| Bandinelli et al. | Case report Stiff skin syndrome and myeloma successfully treated with autologous haematopoietic stem cell transplantation (HSCT) | |
| Fernandez et al. | Review of the novelties presented at the 2018 ECTRIMS Congress: 11th Post-ECTRIMS Meeting (II) | |
| KR20180035911A (ko) | Fgf-18 화합물을 포함하는 조합 조성물 | |
| Mohanan et al. | IGURATIMOD: A NOVEL SMALL MOLECULE DISEASE-MODIFYING ANTIRHEUMATIC DRUG FOR SEROPOSITIVE RHEUMATOID ARTHRITIS-A PROSPECTIVE OBSERVATIONAL STUDY | |
| Živković | Relapsing polychondritis: From etiopathogenesis to therapy | |
| WO2020257173A1 (en) | Method of treating the osteoarthritic joint | |
| Jayashankar et al. | An uncommon variant of rare type of muscular dystrophy | |
| Kim et al. | S-699 Successful use of tocilizumab in a patient with lupus erosive arthritis | |
| HK40060107A (en) | Therapeutic medication for cartilage disorder | |
| NZ745815A (en) | Methods of treatment |